VirginiaBorgesMDMMSc

Hematologic Oncology

Deputy Head, Division of Medical Oncology, University of Colorado Denver School of Medicine

Overview of Dr. Borges

Dr. Virginia Borges is an oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. She received her medical degree from Rutgers New Jersey Medical School and has been in practice 24 years. Dr. Borges accepts several types of health insurance, listed below. She is one of 127 doctors at University of Colorado Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
19802 E 17th Ave
Aurora, CO 80045
Book by Phone+1(720) 804-0052

Fax+1 720-848-1337

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1993 - 1996
Rutgers New Jersey Medical SchoolClass of 1993

Certifications & Licensure

CO State Medical License 2003 - 2025
MA State Medical License 1998 - 2003

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Most Compassionate Doctor American Registry

Clinical Trials

The Young Women's Breast Cancer Study Start of enrollment: 2006 Nov 01
Active, not recruiting
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
The Immune System's Response to Young Women's Breast Cancer Start of enrollment: 2009 Jul 21
Recruiting
Phase 1 Study of ONT-10 in Patients With Solid Tumors Start of enrollment: 2013 Mar 01
Completed
Phase 1
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa Start of enrollment: 2012 Oct 01
Active, not recruiting
Phase 2
Window of Opportunity Study Targeting the Inflammatory Milieu Start of enrollment: 2009 Dec 08
Active, not recruiting
Early Phase 1
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
Completed
Phase 1
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
Completed
Phase 1
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Start of enrollment: 2016 Jan 28
Completed
Phase 2
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Start of enrollment: 2017 Feb 22
Completed
Phase 2
A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer Start of enrollment: 2015 Sep 16
Recruiting
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Start of enrollment: 2020 Dec 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

707 citations
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton
The New England Journal of Medicine. 2020-02-13
46 citations
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Jennifer R. Diamond, S.G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara L. Aisner
Breast Cancer Research. 2018-08-02
63 citations
Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases
Maria J. Contreras-Zarate, Nicole L. Day, D. Ryan Ormond, Virginia F. Borges, Stuart A. Tobet
Oncogene. 2019-02-22

Journal Articles

Estradiol Induces BDNF/TrkB Signaling in Triple-Negative Breast Cancer to Promote Brain Metastases
Virginia Borges, MD, Nature
Mucosal Immunity in the Female Murine Mammary Gland
Virginia Borges, MD, The Journal of Immunology
Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling During Postpartum Mammary Gland Involution and in Breast Cancer
Virginia Borges, MD, Clinical Cancer Research
A Role for Tryptophan-2,3-Dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
Virginia Borges, MD, Clinical Cancer Research
Join now to see all

Press Mentions

Virtual Reality Helps Patients Cope with Difficult Cancer TreatmentsJune 28th, 2022
Study Finds Stereotactic Body Radiotherapy Is Safe for Treating Patients with Multiple MetastasesApril 21st, 2021
Tucatinib ‘Game Changing’ Against HER2+ Breast Cancer, Especially with Brain MetastasesDecember 11th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem KeyCare PPO
Anthem PPO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida BlueSelect
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Carelink Health Plans PPO
Coventry Florida - Employer Group PPO
Coventry Virginia - HMO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment